Liquidia Corp(LQDA) - 2023 Q3 - Earnings Call Transcript

Good morning, team. Roger in the past you've, kind of, discussed YUTREPIA potentially being kind of a prostacyclins at first choice. Maybe you could expand on that thought, especially ahead of a potential launch. Rajeev Saggar Roger Jeffs As of today that patent still has not issued and they've not yet received a notice of issuance. That's a little bit atypical for it to take that long for that patent issue. So, we're not -- we don't have visibility as to what's going on at the United States Patent Trademar ...